Search Results

The three-year agreement leverages AvantGen’s yeast display technology for antibody discovery optimization to engineering antibodies into Antibody-Drug Conjugate treatments.

Adcentrx Therapeutics (“Adcentrx”), and AvantGen, announced today a three-year, multi-target partnership for the discovery of antibodies to be developed into novel ADC therapeutic candidates.

AvantGen, a San Diego-based biotech, is a leader in the use of yeast display technology for human and rabbit monoclonal antibody discovery and optimization.

AvantGen, Inc., a San Diego-based biotechnology company with an array of technology platforms for antibody discovery and optimization, and novel NK and T cell engager generation, today announced licensing of a panel of its anti-SARS-CoV-2 antibody clones to IGM Biosciences for COVID-19 therapy development.

AvantGen, Inc., a privately-held San Diego-based biotechnology company and contract service provider, today announced it has identified and tested fully human synthetic antibodies (“mAbs”) against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2, the “novel Coronavirus”) that show promise for development as diagnostics for SARS-CoV-2 infection and therapeutics for Coronavirus Disease 2019 (COVID-19).

Mark F. Kubik to Lead Business Development and Alliance Management Team

Under the terms of the collaboration, AvantGen is responsible for generating novel antibodies to specified cancer targets using its proprietary human antibody yeast display technology platform.

Antibody research on cancer and neurological diseases is prioritized in series of biopharma research agreements.

Antibody drug conjugates are the novel class of drugs which deliver the chemotherapeutic drug directly to the cancer cell.

- Mr. Kubik joins Actinium with over 25 years of experience in transformative and award-winning BD and M&A transactions - Proven deal making abilities in the empowered antibody, biologics and gene therapy fields strongly suited to Actinium’s AWE technology platform and Antibody Radiation Conjugates for targeted conditioning